Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Breast Cancer (Advanced/Metastatic) · HER2-positive Breast Cancer · Triple-negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Zhen J Peng, Phd) · Zhen-Peng@beijing-biotech.com · +86 13076790039

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Breast Cancer (Locally Advanced or Metastatic) · HER2-positive Breast Cancer · Triple-Negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Irvine, United States · La Jolla, United States

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast Cancer · Breast Cancer Metastatic · Hormone Receptor Positive Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orlando, United States · Atlanta, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China